Diagnostic Concordance and Superiority of Flow Cytometry Over Immunohistochemistry in Acute Leukemia Immunophenotyping: A Single-Center Study.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
BACKGROUND Early diagnosis is crucial for effective treatment and management of acute leukemia. Flow cytometry (FC) is a fast and reliable immunophenotyping technique. This study aimed to compare the diagnostic agreement between FC and histopathological evaluation using shared parameters from bone marrow samples. MATERIAL AND METHODS A total of 144 patients presenting to Adult Hematology, Pediatric Hematology, and Pediatric Oncology clinics at Çukurova University Faculty of Medicine were enrolled; bone marrow samples were processed at the Central Laboratory FC Unit. The cohort included 70 patients with acute myeloid leukemia, 59 with B-cell acute lymphoblastic leukemia, and 15 with T-cell acute lymphoblastic leukemia. The chi-square test, Cohen's kappa, adjusted kappa coefficient, sensitivity, specificity, and accuracy were used to assess FC-IHC concordance. RESULTS The concordance between FC and immunohistochemistry (IHC) was 82.6% for AML (P>0.999, PABAK=0.99) and 61.0% for B-ALL (P=0.054, PABAK=0.89). FC achieved 95% sensitivity for AML and 100% for B-ALL. CD33, MPO, and CD117 showed significant concordance in AML, with sensitivities of 94%, 91%, and 90%, respectively. CD34 was the top-performing biomarker for AML, with 93% sensitivity and 95% specificity. For B-ALL, TdT, CD33, and CD34 showed sensitivities of 77%, 75%, and 81%, respectively. CONCLUSIONS FC showed higher concordance with IHC in AML than in B-ALL and better diagnostic sensitivity for leukemic lineage classification. CD33, MPO, and CD117 were strong AML markers, while TdT, CD33, and CD34 were effective for B-ALL. To quantitatively analyze marker expression with high sensitivity, precise lineage differentiation, and a quick turnaround time, same-day reporting and rapid initiation of targeted therapy make FC essential in modern hematopathology.